Quantitative analysis confirmed that FTO expression was significantly lower in high-grade gliomas (WHO grades III-IV) compared to low-grade gliomas (WHO grades I-II) (Figures 1C,G). The gene discussed is FTO; the disease is central nervous system cancer.